Preexisting Heterotypic Ligand-blocking Antibody Does Not Protect Against Genogroup II Norovirus Episodes in Young Children

• Authors: Sylvia Becker-Dreps, University of North Carolina; Paul D Brewer-Jensen, University of North Carolina; Fredman Gonzalez, National Autonomous University of Nicaragua, León (UNAN-León); Yaoska Reyes, National Autonomous University of Nicaragua, León (UNAN-León); Michael L Mallory, University of North Carolina; Lester Gutierrez, National Autonomous University of Nicaragua, León (UNAN-León); Nadja A Vielot, University of North Carolina; Marta Diez-Valcarce, U.S. Centers for Disease Control and Prevention, Atlanta; Jan Vinje, U.S. Centers for Disease Control and Prevention, Atlanta; Ralph S Baric, University of North Carolina; Lisa C Lindesmith, University of North Carolina; Filemon Bucardo, National Autonomous University of Nicaragua, León (UNAN-León)
• Journal Title: JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY
• Volume: Volume 11, Number 10
• Publisher: OXFORD UNIV PRESS | 2022-07-18, Pages 459-462
• Type of Work: Article | Post-print: After Peer Review
• Publisher DOI: http://doi.org/10.1093/jpids/piac063
• Subjects: Health Sciences, Epidemiology
• Keywords: Science & Technology; Life Sciences & Biomedicine; Infectious Diseases; Pediatrics; children; diarrhea; gastroenteritis; immunity; Nicaragua; norovirus; BIRTH COHORT; GASTROENTERITIS; INFECTIONS; CORRELATE; IMMUNITY

Abstract

A birth cohort design was used to understand whether heterotypic ligand-blocking norovirus antibodies provide cross-protection within the GII genogroup. We found that almost one-half of children who experienced a norovirus GII episode had preexisting antibodies heterotypic to the infecting genotype; therefore, these antibodies did not provide cross-protection.